Tech Company Inital Public Offerings
SCYNEXIS IPO
SCYNEXIS was acquired by . Shares started trading on 5/2/2014.
Transaction Overview
Company Name
Announced On
5/2/2014
Transaction Type
IPO
Amount
$62,000,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Evertrust Plaza 13th Floor
Jersey City, NJ 07302
USA
Jersey City, NJ 07302
USA
Phone
Website
Email Address
Overview
SCYNEXIS, Inc. (NASDAQ: SCYX) is a chemistry-focused drug discovery and development company headquartered in Research Triangle Park, North Carolina. Its scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery of innovative medicines over a broad range of therapy areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marco Taglietti
Chief Financial Officer
Eric Francois
Chief Medical Officer
David Angulo
VP - General Counsel
Scott Sukenick
Browse more venture capital transactions:
Prev: 5/2/2014: Ormet Circuits venture capital transaction
Next: 5/2/2014: Biscayne Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs